Top section
Top section
Both tranches price at the investor-friendly end as cloud company raises to fund expansion
Never mind that your desk had a great year, writes Craig. When it comes to getting paid, the future makes a stronger argument than the past
Top 25 shareholders and new investors participate in previously delayed offering, but some shares left over after subscriptions closed
More articles
More articles
More articles
-
Barclays said it had hired former Deutsche banker Darren Campili as vice-chairman in healthcare banking, part of the UK bank's push to expand its European banking operations. -
To do, or not to do? That appears to be the question plaguing China’s stock exchanges when it comes to including weighted voting rights shares on the Stock Connect’s southbound trading channel. A rather vague consensus has been reached with the Hong Kong bourse, but what does this mean for the city’s equities markets? Jonathan Breen finds out.
-
Hong Kong’s Securities and Futures Commission has sanctioned a former Standard Chartered executive in Hong Kong for IPO-related offences.
-
Shanghai Fosun Pharmaceutical Group bagged HK$2.6bn ($331m) from an H-share placement on Wednesday, its first capital raise in more than a year.
-
Bankers marketing the latest crop of IPOs from China’s technology sector got their game face on this week amid escalating fears of a trade war with the US.
-
Ascletis Pharma is in the market with the first biotechnology IPO in Hong Kong following the bourse’s historic change in listing rules.
Sub-sections
shared comment list
